Smoking alters thromboxane metabolism in man

Area of Science:

• Cardiovascular Science
• Metabolic Research
• Toxicology

Background:

• Chronic smoking is a significant risk factor for atherosclerosis and coronary heart disease.
• Thromboxane A2 (TXA2) plays a crucial role in platelet aggregation and vascular tone.
• Alterations in TXA2 metabolism may contribute to smoking-related cardiovascular pathology.

Purpose of the Study:

• To investigate the urinary excretion patterns of major thromboxane A2 metabolites in chronic smokers.
• To compare TXA2 metabolite profiles between healthy smokers and non-smokers.
• To assess the correlation between urinary cotinine levels and TXA2 metabolite excretion.

Main Methods:

• Measurement of three major TXA2 metabolites: 11-dehydrothromboxane B2, 2,3-dinorthromboxane B2, and thromboxane B2 in urine.
• Comparison of metabolite excretion rates and patterns between 13 healthy smokers and 10 age-matched healthy non-smokers.
• Quantification of urinary cotinine to correlate with smoking intensity.

Main Results:

• Smokers exhibited significantly elevated urinary excretion rates for all measured TXA2 metabolites compared to non-smokers.
• A distinct alteration in the TXA2 metabolite pattern was observed in smokers, characterized by a higher proportion of 2,3-dinorthromboxane B2 (59.2%) versus non-smokers (19.4%).
• Urinary cotinine levels strongly correlated with the excretion of 2,3-dinorthromboxane B2 (r=0.92) and 11-dehydrothromboxane B2 (r=0.87).

Conclusions:

• Chronic smoking alters thromboxane A2 metabolism, potentially contributing to cardiovascular disease risk.
• The shift in TXA2 metabolite profile in smokers highlights a specific metabolic response to nicotine exposure.
• Urinary cotinine serves as a reliable biomarker for smoking intensity and its association with TXA2 pathway activation.